Abstract
Background: To determine efficacy and safety of bevacizumab, a recombinant humanized antibody against vascular endothelial growth factor (VEGF), in the treatment of metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Patients and methods: In this single-arm phase II trial, 32 patients were enrolled and they received bevacizumab 15 mg/kg IV infusion in 21-day cycles. Patients had disease that was deemed not surgically resectable, Eastern Cooperative Oncology Group (ECOG) performance status of <1, adequate organ function and had not received any radiation treatment in the last 28 days. Results: Of the 30 patients evaluated for efficacy and toxic effect, four (two angiosarcoma and two epithelioid hemangioendothelioma; 17%) had a partial response. Fifteen patients (11 angiosarcoma and 4 epithelioid hemangioendothelioma; 50%) showed stable disease with a mean time to progression of 26 weeks. Bevacizumab was well tolerated with only one grade 4 adverse event. Expected known toxic effects of the drug were manageable. Conclusion: Bevacizumab is an effective and well-tolerated treatment for metastatic or locally advanced angiosarcoma and epithelioid hemangioendotheliomas. Further phase III studies of bevacizumab in combination with other chemotherapeutic agents and/or radiation treatment are warranted.
Original language | English (US) |
---|---|
Pages (from-to) | 257-263 |
Number of pages | 7 |
Journal | Annals of Oncology |
Volume | 24 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2013 |
Keywords
- Angiosarcoma
- Bevacizumab
- Hemangioendotheliomas
- Soft tissue sarcoma
ASJC Scopus subject areas
- Hematology
- Oncology